Corcept Q1 revenue $93.7M (+18% YoY); reiterates FY2022 guidance $400-430M

CORCEPT THERAPEUTICS INC

2022-Q1 EPS reported $0.20 revenue$93,688,000

Diluted EPS $0.20 vs $0.18 YoY; cash & investments $368.1M (up $32.3M in Q1).
Phase 3 trial of relacorilant in platinum-resistant ovarian cancer to start this quarter.
GRATITUDE I/II data for miricorilant in antipsychotic weight gain expected Q4 2022.
Relacorilant NDA for Cushing's syndrome now expected H2 2023 (pandemic delays).
Operating expenses $66.9M (+12% YoY) on expanded R&D and legal costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.